1.Simultaneous quantitative analysis of four lignanoids in Schisandra chinensis by quantitative analysis of multi-components by single marker.
Fengcheng HE ; Shouxin LI ; Zhiquan ZHAO ; Jinping DONG ; Wuzhan LIU ; Ruiqiang SU
Acta Pharmaceutica Sinica 2012;47(7):930-3
The aim of the study is to establish a new method of quality evaluation and validate its feasibilities by the simultaneous quantitative assay of four lignanoids in Schisandra chinensis. A new quality evaluation method, quantitative analysis of multi-components by single marker (QAMS), was established and validated with Schisandra chinensis. Four main lignanoids, schisandrin, schisantherin A, deoxyschizandrin and gamma-schizandrin, were selected as analytes and schisandrin as internal reference substance to evaluate the quality. Their contents in 13 different batches of samples, collected from different bathes, were determined by both external standard method and QAMS. The method was evaluated by comparison of the quantitative results between external standard method and QAMS. No significant differences were found in the quantitative results of four lignanoids in 13 batches of S. chinensis determined by external standard method and QAMS. QAMS is feasible for determination of four lignanoids simultaneously when some authentic standard substances were unavailable, and the developed method can be used for quality control of S. chinensis.
2.Content Determination of Three Ginsenosides in Shengmai Ultra-micro Powder
Xinjian QIU ; Shouxin LI ; Wuzhan LIU ; Ruiqiang SU ; Zeping ZHANG ; Zhiquan ZHAO
World Science and Technology-Modernization of Traditional Chinese Medicine 2013;(8):1801-1804
This study was aimed to establish an HPLC method to determine three ginsenosides in Shengmai ultra-micro powder. The kromasil C18 (250 mm í 4.6 mm, 5 μm) was used as analytical column. The mobile phase was composed of acetonitrile (A) and water (B) with gradient elution (0~35 min, 19% A; 35~55 min, 19%~29% A; 55~70 min, 29% A; 70~100 min, 29%~40% A) at a flow rate of 1 mL·min-1. The detection wavelength was 203 nm and the column temperature was 30℃. The injection volume was 10 μL. The results showed that the linear ranges of ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1 were 0.083~0.834 μg, 0.086~0.863 μg, 0.091~0.911 μg, respec-tively. The average recovery rates (n = 6) were 100.7%, 100.5%, 100.5%, respectively. It was concluded that this method was quick, sensitive, repeatable and suitable to determine contents of ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1 in Shengmai ultra-micro powder.
3.Study on improvement of dissolution rate of Yufengningxin Tablets by technique of super fine crushing
Ruiqiang SU ; Yu HE ; Feng LIN ; Jie LI ; Jianmin ZHUANG ; Huarong REN ;
Chinese Traditional Patent Medicine 1992;0(03):-
Objective: To evaluate the affect for quality by crushing technology, The dissolution of Yufengningxin Tablets being prepared by different crushing technology was determined by taking the dissolution of puerarin as test marker. Methods: The Tablets were prepared with the fine powder of Pueraria crude drug which was crushed by normal crusher or super fine crusher. The rotatory basket method was used, the cumulative dissolution percentage was determined by HPLC. Results: Statistics indicated there was a significant difference in dissolution parameter (T 50 ) between super fine crushing powder Tablets and normal fine crushing powder Tablets P
4.Sepration and antitumor activities of secondary metabolites from marine actino-mycete Nocardiopsis sp .SCSIO 11492
Ruiqiang SU ; Yan LI ; Kun PENG ; Jie LI ; Quan YANG ; Xianwen YANG
Journal of Pharmaceutical Practice 2015;(5):406-410
Objective To explore cytotoxic secondary metabolites from a marine actinomycete Nocardiopsis sp .SCSIO 11492 .Methods Isolation and purification were carried out by column chromatography over silica gel ,Sephadex LH-20 ,and ODS structures of the isolates were identified mainly by NMR spectroscopic data .And cytotoxic bioassay was performed using MTT method .Results Five compounds were identified as 2′-deoxyadenosine (1) ,2′-deoxythymidine (2) ,2′-deoxyuidine (3) ,uridine (4) ,1-O-palmitoyl-3-d-galactosyl-sn-glycerol spongilipid (5) .Compound 5 exhibited weak cytotoxic activity with IC50 value of 10 .9 μmol/L .Conclusion Five compounds were obtained from a marine actinomycete Nocardiopsis sp .SCSIO 11492 .All five compounds were reported for the first time from this genus .Compound 5 could be the bioactive compound re-sponsible for the cytotoxic activity of Nocardiopsis sp .SCSIO 11492 .
5.The epigallocatechin gallate derivative Y reverses drug resistance mediated by the ABCB1 transporter both and .
Yan WEN ; Ruiqiang ZHAO ; Pranav GUPTA ; Yingfang FAN ; Yunkai ZHANG ; Zhenguang HUANG ; Xiaohui LI ; Yuangang SU ; Lijuan LIAO ; Yu-An XIE ; Donghua YANG ; Zhe-Sheng CHEN ; Gang LIANG
Acta Pharmaceutica Sinica B 2019;9(2):316-323
Previously, we reported that Y, a new epigallocatechin gallate derivative, is efficacious in reversing doxorubicin (DOX)--mediated resistance in hepatocellular carcinoma BEL-7404/DOX cells. In this study, we evaluated the efficacy of Y in reversing drug resistance both and by determining its effect on the adenosine triphosphate-binding cassette protein B1 transporter (ABCB1 or P-glycoprotein, P-gp). Our results showed that Y significantly sensitized cells overexpressing the ABCB1 transporter to anticancer drugs that are ABCB1 substrates. Y significantly stimulated the adenosine triphosphatase activity of ABCB1. Furthermore, Y exhibited a higher docking score as compared with epigallocatechin gallate inside the transmembrane domain of ABCB1. In addition, in the nude mouse tumor xenograft model, Y (110 mg/kg, intragastric administration), in combination with doxorubicin (2 mg/kg, intraperitoneal injection), significantly inhibited the growth of BEL-7404/DOX cell xenograft tumors, compared to equivalent epigallocatechin gallate. In conclusion, Y significantly reversed ABCB1-mediated multidrug resistance and its mechanisms of action may result from its competitive inhibition of the ABCB1 drug efflux function.